USA – Owkin, an AI-biotech leader, has introduced the next-generation MSIntuit CRC v21, an advanced artificial intelligence (AI) solution designed to transform the detection and treatment of colorectal cancer (CRC).
The new tool, set to launch initially in the United States as a research-use-only (RUO) product, will be integrated with Roche’s Navify digital pathology enterprise software.
This collaboration marks a significant step forward in the precision oncology landscape, combining Owkin’s AI expertise with Roche’s established oncology diagnostic capabilities.
The MSIntuit CRC v2 builds upon the foundation laid by the CE-IVD-certified MSIntuit CRC, an earlier iteration of Owkin’s diagnostic tool.
The latest version includes powerful enhancements, integrating cutting-edge machine learning models developed by Owkin and Roche’s diagnostic technologies.
One of the most significant upgrades is the incorporation of both biopsy and resection analyses, which directly address a crucial gap in the workflow of pathologists.
Dr. Meriem Sefta, Chief Diagnostics Officer at Owkin, stated, “We are thrilled to bring the next innovations in MSIntuit CRC to pathology laboratories, marking a significant advancement in the field of medical diagnostics.
“By leveraging cutting-edge AI technology, we aim to provide more accurate diagnostic tools that will empower pathologists and oncologists to make more informed decisions.”
This breakthrough in diagnostic capabilities is poised to enhance the speed and accuracy of identifying colorectal cancer, offering pathologists a more comprehensive tool to evaluate patient biopsies and resections.
The incorporation of advanced staining techniques, such as haematoxylin and eosin (H&E) and haematoxylin, eosin, and saffron (HES), will further improve diagnostic precision.
Enhancing precision medicine for colorectal cancer
MSIntuit CRC v2 represents a leap forward in precision medicine, a treatment approach that tailors therapies to individual patients based on specific genetic and clinical characteristics.
This AI-powered solution is designed to assist oncologists in selecting the most appropriate treatment plans for CRC patients by improving the accuracy of early cancer detection and ensuring personalized care.
By combining sophisticated machine learning models with Roche’s digital pathology platform, Owkin aims to empower medical professionals with enhanced decision-making tools.
“Our goal is to help deliver highly personalized treatment plans, improving patient outcomes and ensuring that each individual receives the most precise care tailored to their unique medical needs,” Dr. Sefta added.
Impact on pathology and cancer treatment
Owkin’s MSIntuit CRC v2 will soon be available on Roche’s Navify platform, with plans to expand to additional platforms in the near future.
The AI solution will support clinical and research laboratories in diagnosing colorectal cancer with greater accuracy and reliability, helping to identify early-stage disease in more patients and enabling faster access to appropriate treatments.
With more than 150,000 cases of colorectal cancer diagnosed annually in the United States alone, early detection is critical for improving survival rates.
The integration of AI into pathology is expected to reduce diagnostic errors, streamline workflows, and ultimately enhance the efficacy of cancer treatments.
Owkin’s commitment to advancing AI in healthcare
Owkin, founded in 2016, has quickly become a leading force in the integration of AI with biopharmaceutical and healthcare solutions.
The company leverages its AI platform to accelerate drug development, optimize clinical trials, and build innovative diagnostic tools.
Owkin’s mission is to provide advanced, technology-driven solutions to improve patient outcomes across various diseases, with a particular focus on oncology.
In June 2022, the company raised US $80 million in a corporate minority funding round, bringing its total funding to over US $334 million.
With a valuation of US $1 billion as of November 2021, Owkin continues to expand its portfolio of AI-powered healthcare solutions, driving innovation in medical diagnostics and precision medicine.
The competitive landscape in AI-driven pathology
Owkin is in a competitive landscape with other prominent players in the AI-powered pathology and diagnostics space.
Competitors such as PathAI, Paige, and Insilico Medicine are also leveraging machine learning models to improve cancer diagnosis, drug development, and treatment precision.
